MedPharm, the leading global contract development organization for topical and transdermal products, has successfully completed a pre-approval inspection by the FDA at its facility in Durham, NC.
The inspection took place between January 27th and 31st. The FDA inspectors found the site to be compliant and no Form 483 observations issued.
The inspection was triggered by data generated by MedPharm as part of a client’s ANDA for a generic topical product. The ANDA submission used MedPharm’s in vitro models to demonstrate the bioequivalence of the new generic to the originator in line with the new FDA guidelines. The inspection coincides with the recent expansion of the Durham facilities to triple its Center of Excellence footprint and accommodate up to 100 employees in the future.
‘This successful outcome of the inspection by the FDA is a direct reflection of the innovation and quality inherent in everything MedPharm does and a strong endorsement of the integrity and diligence of our scientific team,’ commented Eugene Ciolfi, MedPharm’s President and CEO. ‘I would like to congratulate the Durham team as well as the entire MedPharm global group. This underlines the quality of the sophisticated and proprietary in vitro models MedPharm has developed to de-risk clients’ development programs.
About MedPharm
MedPharm is the world’s leading contract provider of topical and transdermal product design and formulation development services. MedPharm is experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through their unique, cost-effective and industry-leading performance testing models. Well established as the global leaders in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm can also offer innovative solutions for ophthalmic and airway preparations recognised for their scientific rigour by regulators and investors. MedPharm has fully established Centers of Excellence in the USA and the UK.
